Skip to Content

Lenvima Approval History

Lenvima (lenvatinib) is an oral multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of progressive radioiodine-refractory differentiated thyroid cancer and advanced renal cell carcinoma.

Development History and FDA Approval Process for Lenvima

May 13, 2016Approval FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma
Feb 13, 2015Approval FDA Approves Lenvima (lenvatinib) for Differentiated Thyroid Cancer
Feb 12, 2015Lenvatinib Phase III Trial Results Published in New England Journal of Medicine
Jan 30, 2015Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint
Oct 15, 2014U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.